| P2093 | author name string | Markos Leggas | |
| | Tamer A Ahmed | |
| | John Hayslip | |
| P2860 | cites work | Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins | Q24302494 |
| | Dual protein farnesyltransferase-geranylgeranyltransferase-I inhibitors as potential cancer chemotherapeutic agents | Q24306269 |
| | Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked | Q24318845 |
| | Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models | Q28212532 |
| | High accuracy mutation detection in leukemia on a selected panel of cancer genes | Q28728910 |
| | BCL-2 family members and the mitochondria in apoptosis | Q29614427 |
| | The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis | Q29616513 |
| | Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies | Q29616780 |
| | Phase I and pharmacological study of the farnesyltransferase inhibitor tipifarnib (Zarnestra, R115777) in combination with gemcitabine and cisplatin in patients with advanced solid tumours | Q33369069 |
| | Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies? | Q33915429 |
| | DNA damage response and MCL-1 destruction initiate apoptosis in adenovirus-infected cells | Q34278532 |
| | Ras and Rho regulation of the cell cycle and oncogenesis | Q34326213 |
| | K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors | Q34427029 |
| | Function of Ras as a molecular switch in signal transduction | Q35536167 |
| | Farnesyl transferase inhibitors: mechanism of action, translational studies and clinical evaluation | Q35542787 |
| | Farnesyltransferase inhibitors: an overview of the results of preclinical and clinical investigations | Q35549045 |
| | Development of farnesyl transferase inhibitors: a review | Q36263983 |
| | Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets | Q36856455 |
| | The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology | Q36971433 |
| | Role of the MRP1/ABCC1 multidrug transporter protein in cancer | Q37034313 |
| | Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. | Q37109227 |
| | Farnesyltransferase inhibition in hematologic malignancies: the clinical experience with tipifarnib. | Q37170339 |
| | Preclinical versus clinical drug combination studies | Q37330186 |
| | Farnesyltransferase inhibitors: where are we now? | Q37810295 |
| | Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. | Q37865381 |
| | Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. | Q40477698 |
| | MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol | Q40537978 |
| | The Ras signal transduction pathway | Q40733281 |
| | Function and regulation of ras. | Q40835314 |
| | Membrane association and targeting of prenylated Ras-like GTPases | Q40857389 |
| | Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis | Q42467738 |
| | Treatment with high-dose simvastatin inhibits geranylgeranylation in AML blast cells in a subset of AML patients. | Q42723425 |
| | Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells | Q43714923 |
| | Combining simvastatin with the farnesyltransferase inhibitor tipifarnib results in an enhanced cytotoxic effect in a subset of primary CD34+ acute myeloid leukemia samples | Q46041912 |
| | Combining prenylation inhibitors causes synergistic cytotoxicity, apoptosis and disruption of RAS-to-MAP kinase signalling in multiple myeloma cells | Q46698294 |
| | Mutations of the RAS genes in childhood acute myeloid leukemia, myelodysplastic syndrome and juvenile chronic myelocytic leukemia. | Q52829026 |
| | Heterogeneity in simvastatin-induced cytotoxicity in AML is caused by differences in Ras-isoprenylation. | Q54558882 |
| | Pharmacokinetics of high-dose simvastatin in refractory and relapsed chronic lymphocytic leukemia patients. | Q54692331 |
| | Geranylgeraniol overcomes the block of cell proliferation by lovastatin in C6 glioma cells. | Q55477756 |
| | Opinion: Searching for the elusive targets of farnesyltransferase inhibitors | Q75312802 |
| | Use of transporter knockdown Caco-2 cells to investigate the in vitro efflux of statin drugs | Q83743461 |
| P433 | issue | 11 | |
| P921 | main subject | simvastatin | Q670131 |
| P304 | page(s) | 1350-1357 | |
| P577 | publication date | 2014-09-16 | |
| P1433 | published in | Leukemia Research | Q15716445 |
| P1476 | title | Simvastatin interacts synergistically with tipifarnib to induce apoptosis in leukemia cells through the disruption of RAS membrane localization and ERK pathway inhibition | |
| P478 | volume | 38 | |